Feedback
Cystic Fibrosis (CFTR) 165 Pathogenic Variants, Fetal
2013662
Ordering Recommendation

For fetal testing when both parents are known carriers of one of the variants on the CF 165 variants test OR fetus has an echogenic bowel.

Mnemonic
CF VAR FE
Methodology
Polymerase Chain Reaction/Fluorescence Monitoring
Performed
Sun-Sat
Reported
7-10 days
New York DOH Approval Status
This test is New York DOH approved.
ARUP Consult®
Disease Topics
Specimen Required
Patient Preparation
 
Collect
Fetal Specimen: Two T-25 flasks of cultured amniocytes at 80 percent confluency. *If the client is unable to culture amniocytes, this can be arranged by contacting ARUP Client Services at (800) 522-2787.
Maternal Specimen:
Lavender (EDTA), pink (K2EDTA), or yellow (ACD Solution). 
Specimen Preparation
Cultured amniocytes: Fill flasks with culture media. Transport two T-25 flasks of cultured amniocytes at 80 percent confluency. Backup cultures must be retained at the client's institution until testing is complete.
Maternal Specimen:
Transport 3 mL whole blood. (Min. 1 mL) 
Storage/Transport Temperature
Cultured amniocytes: CRITICAL ROOM TEMPERATURE. Must be received within 48 hours of shipment due to lability of cells.
Maternal Specimen:
Refrigerated. 
Unacceptable Conditions
Maternal Specimen: Plasma or serum. Specimens collected in sodium heparin or lithium heparin tubes. 
Remarks
Maternal sample is recommended for proper test interpretation; order Maternal Cell Contamination (ARUP test code 0050608). Patient History Form is available on the ARUP Web site or by contacting ARUP Client Services. 
Stability
Fetal: Ambient: 48 hours; Refrigerated: Unacceptable; Frozen: Unacceptable
Maternal
: Ambient: 72 hours; Refrigerated: 2 weeks; Frozen: 1 month. 
Reference Interval
By report
Interpretive Data
Background information for Cystic Fibrosis (CFTR), 165 Pathogenic Variants, Fetal
Characteristics of Classic Cystic Fibrosis (CF)
: Chronic sino-pulmonary disease, gastrointestinal malabsorption/pancreatic insufficiency, and obstructive azoospermia. Symptoms of mild CF are often limited to a single organ system such as isolated pancreatitis, bilateral absence of the vas deferens, nasal polyposis, or bronchiectasis.
Incidence: 1 in 2,300 Ashkenazi Jewish, 1 in 2,500 Caucasians, 1 in 13,500 Hispanics, 1 in 15,100 African Americans, 1 in 35,100 Asians.
Inheritance: Autosomal recessive.
Penetrance: High for severe and moderately severe pathogenic variants, variable for mild pathogenic variants.
Cause: Two pathogenic CFTR variants on opposite chromosomes.
Pathogenic Variants Tested: Variants are listed by standard nomenclature. Legacy names are also provided for the 23 recommended ACMG variants. c.1A>G, p.Met1Val; c.14C>T, p.Pro5Leu; c.54-5940_273+10250del21kb, p.Ser18ArgfsX16; c.115C>T, p.Gln39X; c.178G>T, p.Glu60X; c.200C>T, p.Pro67Leu; c.223C>T, p.Arg75X; c.254G>A (Legacy G85E), p.Gly85Glu; c.262_263delTT, p.Leu88IlefsX22; c.273+1G>A, Intronic; c.274-1G>A, Intronic; c.274G>A, p.Glu92Lys; c.274G>T, p.Glu92X; c.292C>T, p.Gln98X; c.313delA, p.Ile105SerfsX2; c.325_327delTATinsG, p.Tyr109GlyfsX4; c.328G>C, p.Asp110His; c.349C>T, p.Arg117Cys; c.350G>A (Legacy R117H), p.Arg117His; c.366T>A, p.Tyr122X; c.442delA, p.Ile148LeufsX5; c.489+1G>T (Legacy 621+1G>T); c.509G>A, p.Arg170His; c.531delT, p.Ile177MetfsX12; c.532G>A, p.Gly178Arg; c.579+1G>T (Legacy 711+1G>T); c.579+5G>A, Intronic; c.579+3A>G, Intronic; c.580-1G>T, Intronic; c.595C>T, p.His199Tyr; c.613C>T, p.Pro205Ser; c.617T>G, p.Leu206Trp; c.658C>T, p.Gln220X; c.720_741delAGGGAGAATGATGATGAAGTAC, p.Gly241GlufsX13; c.803delA, p.Asn268IlefsX17; c.933_935delCTT, p.Phe312del; c.948delT, p.Phe316LeufsX12; c.988G>T, p.Gly330X; c.1000C>T (Legacy R334W), p.Arg334Trp; c.1001G>T, p.Arg334Leu; c.1007T>A, p.Ile336Lys; c.1021T>C, p.Ser341Pro; c.1022_1023insTC, p.Phe342HisfsX28; c.1040G>A, p.Arg347His; c.1040G>C (Legacy R347P), p.Arg347Pro; c.1052C>G, p.Thr351Ser; c.1054C>T, p.Arg352Trp; c.1055G>A, p.Arg352Gln; c.1081delT, p.Trp361GlyfsX8; c.1116+1G>A, Intronic; c.1127_1128insA, p.Gln378AlafsX4; c.1153_1154insAT, p.Asn386IlefsX3; c.1202G>A, p.Trp401X; c.1203G>A, p.Trp401X; c.1209+1G>A, Intronic; c.1329_1330insAGAT, p.Ile444ArgfsX3; c.1364C>A (Legacy A455E), p.Ala455Glu; c.1393-1G>A, Intronic; c.1397C>A, p.Ser466X; c.1397C>G, p.Ser466X; c.1400T>C, p.Leu467Pro; c.1418delG, p.Gly473GlufsX54; c.1438G>T, p.Gly480Cys; c.1466C>A, p.Ser489X; c.1475C>T, p.Ser492Phe; c.1477C>T, p.Gln493X; c.1486T>G, p.Trp496Gly; c.1519_1521delATC (Legacy I507del), p.Ile507del; c.1521_1523delCTT (Legacy F508del), p.Phe508del; c.1545_1546delTA, p.Tyr515X; c.1558G>T, p.Val520Phe; c.1572C>A, p.Cys524X; c.1573C>T, p.Gln525X; c.1585-1G>A (Legacy 1717-1G>A); c.1585-8G>A, Intronic; c.1624G>T (Legacy G542X), p.Gly542X; c.1645A>C, p.Ser549Arg; c.1646G>A, p.Ser549Asn; c.1647T>G, p.Ser549Arg; c.1651G>A, p.Gly551Ser; c.1652G>A (Legacy G551D), p.Gly551Asp; c.1654C>T, p.Gln552X; c.1657C>T (Legacy R553X), p.Arg553X; c.1675G>A, p.Ala559Thr; c.1678A>G, p.Arg560Gly; c.1679G>A, p.Arg560Lys; c.1679G>C (Legacy R560T), p.Arg560Thr; c.1680-1G>A, Intronic; c.1703delT, p.Leu568CysfsX4; c.1721C>A, p.Pro574His; c.1753G>T, p.Glu585X; c.1766+1G>A (Legacy 1898+1G>A); c.1766+3A>G, Intronic; c.1792_1798delAAAACTA, p.Lys598GlyfsX11; c.1923_1931del9insA, p.Ser641ArgfsX5; c.1973_1985del13insAGAAA, p.Arg658LysfsX4; c.2012delT, p.Leu671X; c.2051_2052delAA, p.Lys684ThrfsX4; c.2051_2052delAAinsG, p.Lys684SerfsX38; c.2052delA (Legacy 2184delA), p.Lys684AsnfsX38; c.2125C>T, p.Arg709X; c.2128A>T, p.Lys710X; c.2175_2176insA, p.Glu726ArgfsX4; c.2195T>G, p.Leu732X; c.2215delG, p.Val739TyrfsX16; c.2290C>T, p.Arg764Ter; c.2453delT, p.Leu818TrpfsX3; c.2464G>T, p.Glu822X; c.2490+1G>A, Intronic; c.2491G>T, p.Glu831X; c.2506G>T, p.Asp836Tyr; c.2537G>A, p.Trp846X; c.2551C>T, p.Arg851X; c.2583delT, p.Phe861LeufsX3; c.2657+5G>A (Legacy 2789+5G>A); c.2668C>T, p.Gln890X; c.2737_2738insG, p.Tyr913X; c.2780T>C, p.Leu927Pro; c.2810_2811insT, p.Val938GlyfsX37; c.2834C>T, p.Ser945Leu; c.2875delG, p.Ala959HisfsX9; c.2900T>C, p.Leu967Ser; c.2908G>C, p.Gly970Arg; c.2988+1G>A (Legacy 3120+1G>A); c.2988G>A, Intronic; c.2989-1G>A, Intronic; c.3038C>A, p.Pro1013His; c.3039delC, p.Tyr1014ThrfsX9; c.3067_3072delATAGTG, p.Ile1023_Val1024del; c.3140-26A>G, Intronic; c.3194T>C, p.Leu1065Pro; c.3196C>T, p.Arg1066Cys; c.3197G>A, p.Arg1066His; c.3230T>C, p.Leu1077Pro; c.3266G>A, p.Trp1089X; c.3276C>A, p.Tyr1092X; c.3276C>G, p.Tyr1092X; c.3297C>A, p.Phe1099Leu; c.3302T>A, p.Met1101Lys; c.3310G>T, p.Glu1104X; c.3472C>T, p.Arg1158X; c.3484C>T (Legacy R1162X), p.Arg1162X; c.3528delC (Legacy 3659delC), p.Lys1177SerfsX15; c.3587C>G, p.Ser1196X; c.3611G>A, p.Trp1204X; c.3612G>A, p.Trp1204X; c.3659delC, p.Thr1220LysfsX8; c.3717+12191C>T (Legacy 3849+10kbC>T); c.3731G>A, p.Gly1244Glu; c.3744delA, p.Lys1250ArgfsX9; c.3752G>A, p.Ser1251Asn; c.3763T>C, p.Ser1255Pro; c.3764C>A, p.Ser1255X; c.3773_3774insT, p.Leu1258PhefsX7; c.3846G>A (Legacy W1282X), p.Trp1282X; c.3873+1G>A, Intronic; c.3909C>G (Legacy N1303K), p.Asn1303Lys; c.3937C>T, p.Gln1313X; c.3964-78_4242+577del, Exon 22-23 del; c.4028delG, p.Gly1343AlafsX4; c.4046G>A, p.Gly1349Asp; c.4077_4080delTGTTinsAA, p.Val1360fsX3; c.4111G>T, p.Glu1371X; c.4251delA, p.Glu1418ArgfsX14; c.1679+1.6kbA>G. The IVS-8 variant, c.1210-12[5], will be reported when R117H is detected and in individuals that are reported to be symptomatic.
Clinical Sensitivity: Ashkenazi Jewish 96 percent; Caucasian 92 percent; Hispanic 80 percent; African American 78 percent; Asian American 55 percent.
Methodology: Polymerase chain reaction (PCR) and fluorescence monitoring.
Analytical Sensitivity & Specificity: 99 percent.
Limitations: Diagnostic errors can occur due to rare sequence variations. Only the 165 pathogenic CFTR variants listed above will be interrogated.

For quality assurance purposes, ARUP Laboratories will confirm the above result at no charge following delivery. Order Confirmation of Fetal Testing and include a copy of the original fetal report (or the mother's name and date of birth) with the test submission. Please contact an ARUP genetic counselor at (800) 242-2787 extension 2141 prior to specimen submission.

Compliance Statement C: The performance characteristics of this test were validated by ARUP Laboratories. The U.S. Food and Drug Administration (FDA) has not approved or cleared this test. However, FDA approval or clearance is currently not required for clinical use of this test. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions. ARUP is authorized under Clinical Laboratory Improvement Amendments (CLIA) and by all states to perform high-complexity testing. Counseling and informed consent are recommended for genetic testing. Consent forms are available online.

Note
The 165-variant test includes the 23 pathogenic CF variants recommended by the American College of Medical Genetics for population carrier screening.
Components
Component Test Code*Component Chart NameLOINC
0050548Maternal Contamination Study Fetal Spec31208-2
0050612Maternal Contam Study, Maternal Spec31208-2
2013675Cystic Fibrosis, Allele 142938-1
2013676Cystic Fibrosis, Allele 242939-9
2013680Cystic Fibrosis, 165 Var Fetal, Interp38404-0
2013692Cystic Fibrosis 5T Variant21654-9
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
Aliases
  • Fetal CF screening test